Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: Laboratory findings and response to lipid-lowering drugs

Clinical Laboratory

Volumn 59, Issue 7-8, 2013, Pages 901-907

  Wu, Na Qiong ^a   Guo, Yuan Lin ^a   Xu, Rui Xia ^a   Liu, Jun ^a   Zhu, Cheng Gang ^a   Jiang, Li Xin ^a   Li, Jian Jun ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Atherosclerosis; Childhood; Ezetimibe; Homozygous familiar hypercholesterolemia; Rosuvastatin

Indexed keywords

CREATINE KINASE MB; EZETIMIBE; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRO PROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; ROSUVASTATIN; SERINE PROTEINASE; SUBTILISIN; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; AORTA VALVE STENOSIS; ARTICLE; BLOOD PRESSURE; CASE REPORT; CHILD; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY OBSTRUCTION; DISEASE DURATION; ELECTROCARDIOGRAM; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; HEART SOUND; HOMOZYGOTE; HOSPITAL ADMISSION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LIPID BLOOD LEVEL; LIPID STORAGE; MALE; RIGHT CORONARY ARTERY; SCHOOL CHILD; SINUS TACHYCARDIA; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; SYSTOLIC HEART MURMUR; THORAX PAIN; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT RESPONSE;

ADULT; ANTICHOLESTEREMIC AGENTS; CHILD; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 84883245777     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.121104     Document Type: Article

References (21)

1. Guo Y-L, Liu J, Jia Y-J, et al. A multi-center survey of achieving recommended lipid goals in Chinese patients with coronary artery disease in real world cardiovascular practice. Int J Cardiol 2011;153:211-2.
2. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003;111:1795-803. (Pubitemid 38057721)
3. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011;124:2202-7.
4. Palacios L, Grandoso L, Cuevas N, et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 2012;221:137-42.
5. Stefanutti C, Claudia M, Serafina DG. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Curr Med Chem 2012 Sep 3. [Epub ahead of print].
6. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Pro-protein convertase subtilisin/kexin type 9 (PCS K9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011;21:835-43.
7. Cariou B, May CL, Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011;216:258-65.
8. Fahed AC, Safa RM, Haddad FF, et al. Homozygous familial hypercholesterolemia in Lebanese: a genotype/phenotype correlation. Mol Gene Metab 2011;102:181-8.
9. Ozumi K, Tasaki H, Yamashita K, et al. Valvular and supravalvular aortic stenosis in heterozygous familial hypercholesterolemia, a case report. J Atheroscler Thromb 2005; 12:289-93.
10. Soutar AK, Naoumova RP. Mechanism of disease: Genetic causes of familial hypercholesteoemia. Nat Clin Pract Cardiovasc Med 2007;4:214-25. (Pubitemid 46502094)
11. Bozbeyoglu E, Nurkalem Z, Erdem A, Karaci A. Suparavalular aortic stenosis secondary to severe lipid accumulation in the ascending aorta in a patient with uncontrolled familial hyperlipidemia. Arch Turk Soc Cardiol 2011;39:524-5.
12. Can MM, Tanboga IH, Akgun T. Diffuse involvement of aorta in patient with familial hyperlipidemia. ISRN Cardiol 2011;13:17-9.
13. Li J-J, Lu Z-L, Kou W-R, et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from China Coronary Secondary Prevention Study (CCSPS). Ann Med 2010;42:231-40.
14. Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolemic homozygotes in South Africa. BMJ 1980; 281:633-6. (Pubitemid 10051766)
15. Raal JR, Pilcher GJ, Illingworth DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia. Atherosclerosis 1997;135:249-56. (Pubitemid 28015192)
16. Marais AD, Raal FJ, Stein EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia. Atherosclerosis 2008;197:400-6. (Pubitemid 351284477)
17. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe co administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75. (Pubitemid 34568966)
18. Nemati MH, Astaneh B. Optimal management of familial hypercholesterolemia: treatment and management strategies. Vasc Health Risk Manag 2010;6:1079-88.
19. Palcoux JB, Atassi-Dumont M, Lefevre P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008;12:195-201. (Pubitemid 351743600)
20. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 20127;380:29-36.
21. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Pro-protein convertase subtilisin/kexin type 9 (PCS K9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011;21:835-43.